Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

293
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
293
Positron Emission Tomography01:29

Positron Emission Tomography

6.4K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic and Prognostic Value of Hypoxia PET in Glioma: A Systematic Review and Meta-Analysis.

Cancers·2026
Same author

Advances in molecular imaging: diagnostic, technical, and therapeutic considerations-introductory Editorial.

The British journal of radiology·2026
Same author

Advancing radiation oncology care in Ukraine during the war: impact of international observerships on professional development and clinical practice.

Frontiers in oncology·2026
Same author

The PRIMARY Scoring System on PSMA PET for Clinically Significant Prostate Cancer Detection: A Systematic Review and Meta-Analysis.

Clinical nuclear medicine·2026
Same author

Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium.

European journal of human genetics : EJHG·2026
Same author

Correction: Added prognostic value of baseline pre-infusion <sup>18</sup>F-FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy.

Scientific reports·2026

Related Experiment Video

Updated: Nov 4, 2025

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

18.3K

Neuroendocrine Tumors: Imaging Perspective.

Rebecca K S Wong1, Ur Metser2, Patrick Veit-Haibach2

  • 1Radiation Medicine Program, Princess Margaret Cancer Center, University Health Network, 610 University Ave, Toronto, ON M5G 2M9, Canada; Department of Radiation Oncology Temerty Faculty of Medicine, University of Toronto, 149 College Street, Suite 504, Toronto, ON M5T 1P5, Canada.

PET Clinics
|May 31, 2021
PubMed
Summary
This summary is machine-generated.

Positron emission tomography (PET) imaging, particularly with 68Ga-DOTA-peptide, aids in diagnosing and planning treatment for neuroendocrine tumors. This review covers imaging accuracy, dosimetry principles, and predicting patient outcomes.

Keywords:
68-Gallium DOTA-peptidesDosimetryNeuroendocrine tumorsOutcome predictionPET imagingTheranostic

More Related Videos

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
06:44

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Published on: June 7, 2020

7.7K
Multi-modal Imaging of Angiogenesis in a Nude Rat Model of Breast Cancer Bone Metastasis Using Magnetic Resonance Imaging, Volumetric Computed Tomography and Ultrasound
12:23

Multi-modal Imaging of Angiogenesis in a Nude Rat Model of Breast Cancer Bone Metastasis Using Magnetic Resonance Imaging, Volumetric Computed Tomography and Ultrasound

Published on: August 14, 2012

14.5K

Related Experiment Videos

Last Updated: Nov 4, 2025

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

18.3K
Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
06:44

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Published on: June 7, 2020

7.7K
Multi-modal Imaging of Angiogenesis in a Nude Rat Model of Breast Cancer Bone Metastasis Using Magnetic Resonance Imaging, Volumetric Computed Tomography and Ultrasound
12:23

Multi-modal Imaging of Angiogenesis in a Nude Rat Model of Breast Cancer Bone Metastasis Using Magnetic Resonance Imaging, Volumetric Computed Tomography and Ultrasound

Published on: August 14, 2012

14.5K

Area of Science:

  • Nuclear medicine
  • Oncology
  • Radiology

Background:

  • Neuroendocrine tumors (NETs) require precise diagnostic and therapeutic strategies.
  • Functional imaging plays a crucial role in managing NETs.
  • 68Ga-DOTA-peptide PET imaging is a key modality for NETs.

Purpose of the Study:

  • To summarize the utility of PET imaging in neuroendocrine tumor management.
  • To discuss imaging accuracy, dosimetry, and theranostic applications.
  • To review functional imaging's role and outcome prediction in NETs.

Main Methods:

  • Literature review focusing on PET imaging in neuroendocrine tumors.
  • Discussion of 68Ga-DOTA-peptide imaging principles and accuracy.
  • Exploration of dosimetry and theranostic principles.

Main Results:

  • 68Ga-DOTA-peptide PET imaging demonstrates significant accuracy in NET detection and characterization.
  • Individualized dosimetry and theranostic approaches are evolving.
  • Functional imaging data can inform clinical outcome prediction.

Conclusions:

  • PET imaging is integral for the detection, characterization, and therapy planning of neuroendocrine tumors.
  • Dosimetry and theranostics offer personalized treatment strategies.
  • Imaging-derived predictions enhance clinical management of NETs.